2-47471033-T-C

Variant summary

Our verdict is Benign. Variant got -7 ACMG points: 1P and 8B. PP3BP6_Very_Strong

The NM_000251.3(MSH2):​c.1730T>C​(p.Ile577Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000215 in 1,564,106 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I577V) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.00016 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00022 ( 0 hom. )

Consequence

MSH2
NM_000251.3 missense

Scores

11
7
1

Clinical Significance

Likely benign reviewed by expert panel U:8B:15

Conservation

PhyloP100: 7.38
Variant links:
Genes affected
MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -7 ACMG points.

PP3
MetaRNN computational evidence supports a deleterious effect, 0.84
BP6
Variant 2-47471033-T-C is Benign according to our data. Variant chr2-47471033-T-C is described in ClinVar as [Likely_benign]. Clinvar id is 41644.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47471033-T-C is described in Lovd as [Likely_benign].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
MSH2NM_000251.3 linkuse as main transcriptc.1730T>C p.Ile577Thr missense_variant 11/16 ENST00000233146.7

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
MSH2ENST00000233146.7 linkuse as main transcriptc.1730T>C p.Ile577Thr missense_variant 11/161 NM_000251.3 P1P43246-1

Frequencies

GnomAD3 genomes
AF:
0.000164
AC:
25
AN:
152210
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000965
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000139
AC:
35
AN:
250898
Hom.:
0
AF XY:
0.000177
AC XY:
24
AN XY:
135694
show subpopulations
Gnomad AFR exome
AF:
0.0000620
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000282
Gnomad OTH exome
AF:
0.000164
GnomAD4 exome
AF:
0.000221
AC:
312
AN:
1411896
Hom.:
0
Cov.:
25
AF XY:
0.000203
AC XY:
143
AN XY:
705500
show subpopulations
Gnomad4 AFR exome
AF:
0.0000308
Gnomad4 AMR exome
AF:
0.0000448
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000282
Gnomad4 OTH exome
AF:
0.000136
GnomAD4 genome
AF:
0.000164
AC:
25
AN:
152210
Hom.:
0
Cov.:
32
AF XY:
0.000108
AC XY:
8
AN XY:
74366
show subpopulations
Gnomad4 AFR
AF:
0.0000965
Gnomad4 AMR
AF:
0.0000654
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000269
Hom.:
0
Bravo
AF:
0.000196
TwinsUK
AF:
0.000809
AC:
3
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000349
AC:
3
ExAC
AF:
0.000132
AC:
16
EpiCase
AF:
0.000327
EpiControl
AF:
0.00

ClinVar

Significance: Likely benign
Submissions summary: Uncertain:8Benign:15
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not provided Uncertain:3Benign:6
Likely benign, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoSep 18, 2020- -
Likely benign, no assertion criteria providedclinical testingClinical Genetics, Academic Medical Center-- -
Likely benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Uncertain significance, no assertion criteria providedresearchBiesecker Lab/Clinical Genomics Section, National Institutes of HealthJul 13, 2012- -
Likely benign, no assertion criteria providedclinical testingClinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute-- -
Likely benign, criteria provided, single submitterclinical testingGeneDxJul 06, 2020This variant is associated with the following publications: (PMID: 27958275, 22703879, 16636019, 19117025, 22006311, 16736289, 16885385, 21056691, 25871441, 16408224, 26878173, 26182300) -
Likely benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesOct 23, 2023- -
Uncertain significance, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The MSH2 p.Ile577Thr variant was identified in 6 of 1950 proband chromosomes (frequency: 0.003) from individuals or families with endometrial, colorectal, and ovarian cancer (Hampel 2006, Limburg 2011, South 2009, Spaepen 2006, Walsh 2011), and was present in 1 of 1142 control chromosomes (frequency: 0.0009) from healthy individuals (Johnston 2012). The variant was also identified in dbSNP (ID: rs63749910) as “With Uncertain significance allele”, ClinVar (as likely benign, reviewed by expert panel and Ambry Genetics, and as uncertain significance by GeneDx, Invitae, Knight Diagnostics, Laboratory for Molecular Medicine, Quest Diagnostics, Integrated Genetics, and Biesecker Lab), Clinvitae (6x), UMD-LSDB (1x as uncertain significance), Insight Colon Cancer Gene Variant Database (5x as "class 2 likely not pathogenic"), and Mismatch Repair Genes Variant Database (1x). The variant was not identified in COGR, Cosmic, MutDB, or Zhejiang University Database. The variant was identified in control databases in 41 of 276890 chromosomes at a frequency of 0.0001 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 2 of 24008 chromosomes (freq: 0.00008), Other in 1 of 6458 chromosomes (freq: 0.0002), Latino in 1 of 34416 chromosomes (freq: 0.00003), and European (Non-Finnish) in 37 of 126452 chromosomes (freq: 0.0003); it was not observed in the Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. One study reported the variant was found to co-occur with a pathogenic MUTYH variant: c.36+1G>A (Niessen 2006). The p.Ile577 residue is conserved in mammals but not in more distantly related organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
not specified Uncertain:2Benign:2
Likely benign, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalAug 15, 2023- -
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 07, 2021Variant summary: MSH2 c.1730T>C (p.Ile577Thr) results in a non-conservative amino acid change located in the DNA mismatch repair protein MutS, core domain (IPR007696) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00015 in 251570 control chromosomes, predominantly at a frequency of 0.00028 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not significantly higher than expected for a pathogenic variant in MSH2 causing Hereditary Nonpolyposis Colorectal Cancer (0.00015 vs 0.00057), allowing no conclusion about variant significance. c.1730T>C has been reported in the literature in individuals affected with colorectal cancer, endometrial cancer, ovarian cancer and hereditary diffuse gastric cancer (Spaepen_2006, Niessen_2006, Limburg_2011, Hampel_2006, South_2009, Hansford_2015) without strong evidence of causality. Many of these tumors show normal MSH2 expression by immunohistochemistry. In one patient absence of MLH1 (but normal expression of MSH2) protein was seen together with methylation of MLH1 promoter region suggestive of an alternative etiology and molecular basis of disease in this patient (Hampel_2006). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer/Lynch syndrome. At-least two co-occurrences with other pathogenic variant(s) have been reported in the literature and also observed at our laboratory ( MUTYH c.36+1G>A, Niessen_2006; BRCA1 c.3005delA , p.Asn1002fsX22 at our laboratory), providing supporting evidence for a benign role. A study that computed a tumor characteristic likelihood ratio (TCLR) in combination with in-silico predictors and multifactorial variant prediction (MVP) model including allele frequency, co-occurrence, co-segregation, clinical and family history information classified this variant a benign (Li_2020). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign/benign, n=4; VUS, n=5). Based on the evidence outlined above, the variant was classified as benign. -
Uncertain significance, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineJan 25, 2017Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Classified within the last year. This variant has been reported in 1 indidivual who did not have cancer, and 1 individual with CRC. The variant has a Max MAF of 0.02% in ExAC (14 alleles) and 0.03% in gnomAD (38 alleles). It is classified with 3 stars in ClinVar as Likely benign by an expert panel (InSiGHT) and Ambry, and VUS by GeneDx, Invitae, and Biesecker lab. -
Uncertain significance, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoDec 16, 2019DNA sequence analysis of the MSH2 gene demonstrated a sequence change, c.1730T>C, in exon 11 that results in an amino acid change, p.Ile577Thr. This sequence change has been described previously in individuals with colorectal cancer, ovarian cancer or adenocarcinoma of the endometrium (PMID: 21056691, PMID: 19117025, PMID: 16885385, PMID: 16736289). It has been described in the gnomAD database with a low population frequency of 0.029% in non-Finnish European subpopulation (dbSNP rs63749910). The p.Ile577Thr change affects a moderately conserved amino acid residue located in a domain of the MSH2 protein that is known to be functional. The p.Ile577Thr substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these evidences and the lack of functional studies, the clinical significance of the p.Ile577Thr change remains unknown at this time. -
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthJan 02, 2022- -
Likely benign, criteria provided, single submitterclinical testingAmbry GeneticsSep 20, 2018This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Likely benign, criteria provided, single submittercurationSema4, Sema4Jun 19, 2021- -
Lynch syndrome 1 Uncertain:2
Uncertain significance, no assertion criteria providedclinical testingKnight Diagnostic Laboratories, Oregon Health and Sciences UniversityMar 30, 2016- -
Uncertain significance, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaMay 16, 2019This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioMar 02, 2021- -
MSH2-related disorder Benign:1
Likely benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesMay 12, 2021This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Hereditary nonpolyposis colon cancer Benign:1
Benign, criteria provided, single submitterclinical testingMendelicsAug 22, 2023- -
Lynch syndrome Benign:1
Likely benign, reviewed by expert panelresearchInternational Society for Gastrointestinal Hereditary Tumours (InSiGHT)Sep 05, 2013Multifactorial likelihood analysis posterior probability 0.001-0.049 -
Hereditary nonpolyposis colorectal neoplasms Benign:1
Likely benign, criteria provided, single submitterclinical testingInvitaeJan 31, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.89
BayesDel_addAF
Pathogenic
0.25
D
BayesDel_noAF
Pathogenic
0.43
CADD
Pathogenic
26
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.81
D;.;.;.
Eigen
Pathogenic
0.74
Eigen_PC
Pathogenic
0.75
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Pathogenic
0.98
D;D;D;D
M_CAP
Uncertain
0.29
D
MetaRNN
Pathogenic
0.84
D;D;D;D
MetaSVM
Pathogenic
0.85
D
MutationAssessor
Uncertain
2.7
M;.;.;.
MutationTaster
Benign
1.0
D;D;D
PrimateAI
Uncertain
0.68
T
PROVEAN
Uncertain
-3.6
D;D;.;D
REVEL
Pathogenic
0.93
Sift
Uncertain
0.0030
D;D;.;D
Sift4G
Uncertain
0.0070
D;D;.;D
Polyphen
0.92
P;.;.;P
Vest4
0.94
MVP
0.98
MPC
0.016
ClinPred
0.45
T
GERP RS
5.9
Varity_R
0.69
gMVP
0.74

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs63749910; hg19: chr2-47698172; COSMIC: COSV51886801; API